Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia
2018 ◽
Vol 36
(32)
◽
pp. 3183-3185
◽